The pandemic provided the best and worst of times for smid-cap medtechs.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
Intuitive Surgical makes the most money per employee – but the title of “most improved” goes to Philips.
Investor excitement about smaller medtechs’ technology is unchecked, but these groups will have to deliver on their promises.
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.